DSM in the news
Global leader health nutrition
Tamtam found 20 recent articles about DSM.
- DSM-Firmenich stock last at EUR 99.84 on Xetra on October 6, 2026
DSM-Firmenich completed a share repurchase program and introduced a new Sustell capability for farm footprint calculations.
- dsm-firmenich expands environmental footprinting with farm-level crop data
dsm-firmenich's Sustell® platform now incorporates farm-level crop data to improve the accuracy of environmental footprinting for animal protein production.
- DSM-Firmenich stock follows completion of EUR 540 million buyback
DSM-Firmenich completed a EUR 540 million share buyback, while reporting solid first-half 2026 financial results and receiving mixed analyst ratings.
- dsm-firmenich belooft marge maar de kas moet nog volgen
dsm-firmenich aims for a 20% adjusted EBITDA margin and 11-12% adjusted gross operating free cash flow by 2026, with current net debt at •4.424 billion.
- Verdwijnen er na de inkoop van dsm-firmenich echt aandelen?
dsm-firmenich completed a 540 million euro share repurchase program; however, the actual value depends on the net reduction in shares after accounting for new issuances and the impact on free cash flow per share.
- Can DSM-Firmenich (ENXTAM:DSFIR) Stay Cheap After A 40% Rally?
DSM-Firmenich's stock has rallied significantly, leading to an analysis of whether its cash flows and future growth, particularly from its CORNEOCARE 2.0 platform, justify its current share price according to a Discounted Cash Flow model.
- DSM-Firmenich rondt aandeleninkoop af
DSM-Firmenich completed a 540 million euro share repurchase program aimed at employee remuneration and capital reduction.
- DSM-Firmenich rondt aandeleninkoop af
DSM-Firmenich completed a 540 million euro share repurchase program aimed at funding employee incentives and reducing capital, resulting in a 2.6% decrease in outstanding shares.
- DSM-Firmenich (ENXTAM:DSFIR) Could Be 3% Overvalued After Its €540 Million Buyback
DSM-Firmenich completed a –540 million share repurchase program, leading to a 3% overvaluation according to one narrative, while another model suggests undervaluation.
- DSM-Firmenich stock after-hours at EUR 95.98: minus 1.40 percent versus prior close
DSM-Firmenich's stock saw a 1.40% after-hours decline to EUR 95.98, following the completion of its EUR 540 million share repurchase program.
- dsm-firmenich launches Biond pharmaceutical-grade vitamin portfolio for cell culture and biologics manufacturing
dsm-firmenich introduced Biond, a new line of pharmaceutical-grade vitamins for biopharmaceutical applications, distributed globally through a partnership with Brenntag Pharma.
- DSM-Firmenich:
DSM-Firmenich extended its social plan until July 31, 2028, following trade union requests amid a reorganization, while also seeking a statement on responsible collective bargaining.
- Innovation Powerhouse: How Singapore is helping Dell, Evonik and dsm-firmenich stay ahead of the competition
Global companies like Dell, Evonik, and dsm-firmenich are leveraging Singapore's innovative ecosystem and strategic location to deepen their R&D and expand across Asia.
- Brenntag and dsm-firmenich launch BYPHAR powered by Biond for GMP-grade biologics vitamin supply
Brenntag Pharma and dsm-firmenich partnered to distribute GMP-grade vitamins globally under the new co-brand BYPHAR powered by Biond for biologics manufacturing.
- Deutsche Bank verhoogt koersdoel DSM-Firmenich licht
Deutsche Bank raised DSM-Firmenich's price target to 107.00 euros, maintaining a 'buy' rating and forecasting solid Q3 revenue growth and increased EBITDA.
- Citi verhoogt koersdoel DSM-Firmenich
Citi Research increased its price target for DSM-Firmenich to 111 euros, citing strong recovery potential driven by margin improvements and strategic execution.
- dsm-firmenich boekt de eerste fusiesynergie en toch moet 115 miljoen euro daarvan nog binnenkomen
dsm-firmenich has booked initial merger synergies but faces the challenge of realizing an additional •115 million EBITDA by 2027, dependent on converting sales and cost efficiencies into free cash flow and maintaining customer relationships.
- POET-DSM: Project Liberty
POET-DSM's Project LIBERTY biorefinery began producing cellulosic ethanol from corn stover, aiming to boost fuel independence, reduce climate impacts, and create jobs.
- dsm-firmenich Beauty & Care advances epidermal science at IFSCC Congress 2026 with CORNEOCARE™ 2.0
dsm-firmenich Beauty & Care is presenting its CORNEOCARE™ 2.0 platform and research on pigmentation control at the IFSCC Congress 2026.
- dsm-firmenich benoemt Inge Massen-Biemans tot Chief Sustainability Officer
dsm-firmenich appointed Inge Massen-Biemans as Chief Sustainability Officer, effective November 1, 2026, succeeding Katharina Stenholm.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like DSM?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies